Social Determinants of Health and their Impact on COVID-19

Immunological and Autoimmune Disorders

Cumberland’s methotrexate product gets approva...

Cumberland Pharmaceuticals has recently received approval from the US FDA for its RediTrex injection for the treatment of rheumatoid arthritis. Cumberland pharmaceuticals pharma company focusing on...

Dec 03, 2019

Pharma News
Novartis buys Medicines; Blackstone Life Sciences and Ferring’s collaboration; Alexion’s Soliris (eculizumab) Approval;

Novartis plans to buy The Medicines Company for USD 9.7 Billion to gain access to a heart drug inclisiran, almost ready to get into the market. Under the terms of the deal, Novartis will pay USD 85 per share to the Medicines Company, a cholesterol drug developer, making the deal up to USD 9.7 Billion. The whole...

Find More
Biosimilar Market
The long journey of Biosimilars: Is it an emerging opportunity?

Biologics are not new drugs, their use as a medicine has been around for over a century. The first use of Biologic drug dates back to the year 1796 when the vaccine to treat smallpox was created.They have been revolutionizing the treatment approaches for the past many years. Hormones, insulin, blood products, cytok...

Find More
Pharma news
AbbVie Sells bonds to Fund Allergan takeover

AbbVie has traded off its bonds worth USD 30 Billion to finance the purchase of the Allergan.   AbbVie this year in June has agreed to buy Allergan for USD 63 Billion, which is one of the largest deals this year. The acquisition will help AbbVie to diversify its drug portfolio which mostly revolves around H...

Find More

More Views & Analysis

Pharma News
AZ sells EU rights for Schizophrenia to Cheplapharm; Astellas, Pandion unite to extract the potential of immunomodulation; Pear therapeutics on a journey to develop digital GI treatments with Ironwood

AstraZeneca has announced the licensing-out of two of its drugs Seroquel and Seroquel XR in Europe and Russia to Cheplapharm Arzneimittel GmbH. According to the deal signed between the companies, AZ will receive an upfront payment of USD 178 Million, in addition to other payments upon achieving sales milestones...

Find More

Graft versus host disease
Incyte Corporation submits positive results of trials for its drug Ruxolitinib in GvHD

Incyte Corporation has recently announced the results of Novartis-sponsored Phase III clinical trials REACH2 evaluating its candidate Ruxolitinib (Jakafi) in patients suffering from steroid-refractory acute graft-versus-host disease (GvHD). Graft versus host disease (GvHD), as defined by the National Cancer Institu...

Find More

World Pharma News
AngioDynamics acquires Eximo; MiroBio raises USD 33 M; Janssen submits sBLA for Stelara

AngioDynamics, an innovative medical devices provider, has signed an upfront USD 46 Million deal to acquire Eximo Medical. AngioDynamics is a leading player in manufacturing medical devices for vascular access, peripheral vascular disease, and oncology. The acquisition of Eximo Medical will increase the portfol...

Find More

Peanut allergy
FDA is reviewing a dangerous way to treat Peanut Allergy

Peanut allergies (PA) are the most common and severe type of food allergies in children. Even a small fragment of this legume to an allergic person can result in permanent brain damage.  The prevalence rate of the Peanut allergy, over the past two decades, has tripled. According to DelveInsight, total prevalen...

Find More

Lupus Nephritis
Roche’s Gazyva receives FDA Breakthrough designation for Lupus nephritis

The US FDA has in a recent move granted Roche’s Gazyva Breakthrough Therapy Designation (BTD) for adults with lupus nephritis. Gazyva (obinutuzumab) is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. Classified as a "monoclonal antibody", Gazyva is a CD20-directed cytolytic antibody. The drug...

Find More

Pharma News
Fujifilm acquires global rights to Cynata’s novel therapy for GvHD; Themis raises EURO 40 million for Chikungunya vaccine; Bayer to license One Drop’s digital diabetes platform

FUJIFILM Corporation has signed an exclusive licensing agreement with an Australian bio-venture Cynata Therapeutics Limited for CYP-001. Under the agreement, FUJIFILM will gain rights to develop, manufacture and market a drug for the treatment of graft-versus-host disease (GvHD). CYP-001 is a Cynata’s lead cand...

Find More

Advances in continuous glucose monitoring (CGM) has led to a paradigm shift in the management of typ.....

Find More

Cocaine Use Disorder (CUD) is characterized as a substance use disorder in which biological, psychol.....

Find More

Though Covid-19 has a significant impact on the supply chain, input costs, logistics, and raw materi.....

Find More

A rare neurological disorder characterized by progressive weakness and impaired sensory function in .....

Find More

Wearable technology has been gaining momentum for the last few years as an effect of the fourth indu.....

Find More

Toll-like receptors (TLR) 7 and 8 are functionally localized to endosomes and recognize specific RNA.....

Find More